117亿美元！全球药企巨头再现巨额并购

华尔街见闻2021-12-14

12月14日，据路透社报道，澳大利亚生物技术公司CSL同意以117亿美元收购瑞士制药商Vifor Pharma AG，以增加一套治疗肾病和缺铁症的治疗方法，使产品更加多元化。 CSL表示，将以每股179.25美元的价格收购所有公开发行的Vifor股票，相当于截止至12月1日60天平均股价溢价40%。CSL将通过45亿美元的机构配售为此次收购提供部分资金。此次融资是澳大利亚二级市场规模最大的交易...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

jhanwei
2021-12-14
jhanwei
[微笑]
- LNM888:
  ok
一剑奈何
2021-12-14
一剑奈何
Ok
- 一剑奈何:
  Ok

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2191930766?lang=zh_CN&edition=full","thumbnail":"https://static.tigerbbs.com/a2b8c3b51114fd73abb93d39ddbf6e91","is_english":false,"pubTime":"2021-12-14 21:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2191930766","market":"us","top_or_hot":-1,"title":"117亿美元！全球药企巨头再现巨额并购","media":"华尔街见闻","content":"<div>\n<p>12月14日，据路透社报道，澳大利亚生物技术公司CSL同意以117亿美元收购瑞士制药商Vifor Pharma AG，以增加一套治疗肾病和缺铁症的治疗方法，使产品更加多元化。\nCSL表示，将以每股179.25美元的价格收购所有公开发行的Vifor股票，相当于截止至12月1日60天平均股价溢价40%。CSL将通过45亿美元的机构配售为此次收购提供部分资金。\n此次融资是澳大利亚二级市场规模最大的交易...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3647284\">网页链接</a>\n\n</div>\n","source":"wallstreetcn_api","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>117亿美元！全球药企巨头再现巨额并购</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n117亿美元！全球药企巨头再现巨额并购\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-12-14 21:26 北京时间&nbsp;&nbsp;&nbsp;<a href=https://wallstreetcn.com/articles/3647284><strong>华尔街见闻</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>12月14日，据路透社报道，澳大利亚生物技术公司CSL同意以117亿美元收购瑞士制药商Vifor Pharma AG，以增加一套治疗肾病和缺铁症的治疗方法，使产品更加多元化。\nCSL表示，将以每股179.25美元的价格收购所有公开发行的Vifor股票，相当于截止至12月1日60天平均股价溢价40%。CSL将通过45亿美元的机构配售为此次收购提供部分资金。\n此次融资是澳大利亚二级市场规模最大的交易...</p>\n\n<a href=\"https://wallstreetcn.com/articles/3647284\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4568","symbol_name":"美国抗疫概念","start_time":0,"source_url":"https://wallstreetcn.com/articles/3647284","article_id":"2191930766","we_media_id":null,"thumbnails":["https://static.tigerbbs.com/a2b8c3b51114fd73abb93d39ddbf6e91"],"rights":{"source":"wallstreetcn_api","url":"https://wallstreetcn.com/articles/3647284","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2191930766","pubTimestamp":1639488367,"sourceInfo":{"source_id":"wallstreetcn_api","name":"华尔街见闻"},"weMediaInfo":null,"summary":"12月14日，据路透社报道，澳大利亚生物技术公司CSL同意以117亿美元收购瑞士制药商Vifor Pharma AG，以增加一套治疗肾病和缺铁症的治疗方法，使产品更加多元化。\nCSL表示，将以每股17","collect":0,"end_time":0,"defaultTopTitle":"wallstreetcn.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4568":"美国抗疫概念","AZN":"阿斯利康","BK4007":"制药"},"translate_title":"$11.7 billion! Global pharmaceutical giants reproduce huge mergers and acquisitions","themeId":null,"isJumpTheme":false,"ttsUrl":"https://static.tigerbbs.com/12dff3949d7eae92de53489a349e28ce","symbols_score_info":{"AZN":0.9},"content_text":"12月14日，据路透社报道，澳大利亚生物技术公司CSL同意以117亿美元收购瑞士制药商Vifor Pharma AG，以增加一套治疗肾病和缺铁症的治疗方法，使产品更加多元化。\nCSL表示，将以每股179.25美元的价格收购所有公开发行的Vifor股票，相当于截止至12月1日60天平均股价溢价40%。CSL将通过45亿美元的机构配售为此次收购提供部分资金。\n此次融资是澳大利亚二级市场规模最大的交易之一，也是今年全球二级市场十大交易之一。\n血液及疫苗巨头CSL是澳大利亚市值最大的公司之一，也是阿斯利康在澳大利亚唯一的新冠疫苗生产商。CSL公司拥有百年历史，2000年之后，通过不断扩张收购，奠定了其在血液制品和流感疫苗方面的优势。而此次并购可以使其获得Vifor治疗缺铁、肾脏和心肾疾病的技术专利，以及在瑞士和葡萄牙的生产基地。\n自从疫情以来，相关限制严重打击了血液制品业务，是CSL相关业务利润下滑了近90%。\n而此项交易的完成预计将为其增加收益，使其开发阶段的产品线扩大至37种，比目前的产品线增加32%。\nVifor的重磅药物是缺铁治疗药物Ferinject/Injectafer，该药物2021年上半年的销售额占总销售额的三分之一。\nCSL表示，Vifor董事会一致通过了该要约，其最大股东Patinex AG也同意出让其股份。\nCSL将通过向机构和散户投资者配售价值约50亿美元的股票、60亿美元的债券以及20亿美元的现有资金和未动用设施为该交易提供资金。\n受到潜在交易的消息刺激，Vifor的股价自12月初以来已飙升逾三分之一。该股价曾在2020年2月曾触及190法郎的高点，随后持续下跌，目前约120法郎。\nCSL的报价较Vifor12月1日收盘价高出约40%。目前Vifor股价上涨12%，至157.30法郎。\n\nCSL的开盘价为273澳元，较周一收盘价297.27澳元回撤了8.2%，此后暂停交易。","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":607369502,"gmtCreate":1639490887615,"gmtModify":1639490887615,"author":{"id":"4099234321752210","authorId":"4099234321752210","name":"jhanwei","avatar":"https://static.tigerbbs.com/94dcc95a1ac0654b55469c88be3ad768","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"[微笑]&nbsp;","listText":"[微笑]&nbsp;","text":"[微笑]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607369502","repostId":2191930766,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6980468,"gmtCreate":1639494835236,"gmtModify":1639494835267,"authorId":4088090190949440,"author":{"id":4088090190949440,"authorId":4088090190949440,"name":"LNM888","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":607369502,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":607389430,"gmtCreate":1639489784221,"gmtModify":1639489784297,"author":{"id":"3586266967551836","authorId":"3586266967551836","name":"一剑奈何","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0},"htmlText":"Ok&nbsp;","listText":"Ok&nbsp;","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/607389430","repostId":2191930766,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6979167,"gmtCreate":1639489792047,"gmtModify":1639489792073,"authorId":3586266967551836,"author":{"id":3586266967551836,"authorId":3586266967551836,"name":"一剑奈何","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":607389430,"type":1,"supId":0,"prevId":0,"content":"Ok ","text":"Ok ","html":"Ok "}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":19,"commentSize":2,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2191930766"}